Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes (Q37938745)

25 August 2017

1 reference

title

Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes (English)

1 reference

25 August 2017

1 reference

Zemin Cao

1

1 reference

25 August 2017

Mark E Cooper

series ordinal

2

1 reference

25 August 2017

publication date

25 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

49

1 reference

25 August 2017

issue

4

1 reference

25 August 2017

page(s)

243-254

1 reference

Projections of global mortality and burden of disease from 2002 to 2030

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Standards of medical care in diabetes--2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

The role of the renin-angiotensin system in the development of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

AT(1) receptors and control of blood pressure: the kidney and more...

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

The AT2 receptor--a matter of love and hate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Molecule-specific effects of angiotensin II-receptor blockers independent of the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Telmisartan: a different angiotensin II receptor blocker protecting a different population?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Telmisartan: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Results of treatment with telmisartan-amlodipine in hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Effects of renin-angiotensin system blockade on the islet morphology and function in rats with long-term high-fat diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Next generation multifunctional angiotensin receptor blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Renin-angiotensin system and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Cough with ACE inhibitors: a bigger problem in some racial groups?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Beneficial impact of spironolactone in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0328-3

10.1007/S00592-011-0328-3

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference